AU2002256615B2 - 6-substituted pyrido-pyrimidines - Google Patents

6-substituted pyrido-pyrimidines Download PDF

Info

Publication number
AU2002256615B2
AU2002256615B2 AU2002256615A AU2002256615A AU2002256615B2 AU 2002256615 B2 AU2002256615 B2 AU 2002256615B2 AU 2002256615 A AU2002256615 A AU 2002256615A AU 2002256615 A AU2002256615 A AU 2002256615A AU 2002256615 B2 AU2002256615 B2 AU 2002256615B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
cycloalkyl
hydrogen
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002256615A
Other languages
English (en)
Other versions
AU2002256615A1 (en
Inventor
Jian Jeffrey Chen
James Patrick Dunn
David Michael Goldstein
Christoph Martin Stahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2002256615A1 publication Critical patent/AU2002256615A1/en
Application granted granted Critical
Publication of AU2002256615B2 publication Critical patent/AU2002256615B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2002256615A 2001-02-12 2002-02-04 6-substituted pyrido-pyrimidines Expired AU2002256615B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26837501P 2001-02-12 2001-02-12
US60/268,375 2001-02-12
US33465401P 2001-11-30 2001-11-30
US60/334,654 2001-11-30
PCT/EP2002/001106 WO2002064594A2 (en) 2001-02-12 2002-02-04 6-substituted pyrido-pyrimidines

Publications (2)

Publication Number Publication Date
AU2002256615A1 AU2002256615A1 (en) 2003-02-20
AU2002256615B2 true AU2002256615B2 (en) 2007-09-13

Family

ID=26953040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002256615A Expired AU2002256615B2 (en) 2001-02-12 2002-02-04 6-substituted pyrido-pyrimidines

Country Status (31)

Country Link
US (3) US6696566B2 (https=)
EP (1) EP1361880B1 (https=)
JP (1) JP4064818B2 (https=)
KR (1) KR100639772B1 (https=)
CN (1) CN100376571C (https=)
AR (1) AR035854A1 (https=)
AT (1) ATE305303T1 (https=)
AU (1) AU2002256615B2 (https=)
BR (1) BRPI0207172B8 (https=)
CA (1) CA2434834C (https=)
CZ (1) CZ20032416A3 (https=)
DE (1) DE60206363T2 (https=)
DK (1) DK1361880T3 (https=)
ES (1) ES2249574T3 (https=)
HR (1) HRP20030624B1 (https=)
HU (1) HU229604B1 (https=)
IL (2) IL156872A0 (https=)
JO (1) JO2410B1 (https=)
MA (1) MA26993A1 (https=)
MX (1) MXPA03007166A (https=)
MY (1) MY131518A (https=)
NO (1) NO326133B1 (https=)
NZ (1) NZ526961A (https=)
PA (1) PA8539201A1 (https=)
PE (1) PE20020976A1 (https=)
PL (1) PL366918A1 (https=)
RU (1) RU2269527C2 (https=)
SK (1) SK11322003A3 (https=)
WO (1) WO2002064594A2 (https=)
YU (1) YU63703A (https=)
ZA (1) ZA200305938B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003237009B2 (en) * 2002-01-22 2008-10-02 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3d]pyrimidin-7-ones

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
DE60206363T2 (de) 2001-02-12 2006-07-06 F. Hoffmann-La Roche Ag 6-substituierte pyridopyrimidine
EP1492790A1 (en) 2002-04-03 2005-01-05 F. Hoffmann-La Roche Ag Imidazo fused compounds
CA2492112A1 (en) * 2002-08-06 2004-02-19 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2517256C (en) * 2003-02-26 2013-04-30 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
AU2004229163A1 (en) * 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag (6-(phenoxy)-pyrido`3,4-d! PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORYY CONDITIONS SUCH AS RHEUMATOIS ARTRITIS
WO2005047284A1 (en) * 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
EP1831215A1 (en) * 2004-11-23 2007-09-12 Ranbaxy Laboratories Limited Pyrido[2,3-d]pyrimidines as anti-inflamatory agents
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
EP1846403A1 (en) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Azabicyclo derivatives as anti-inflammatory agents
MX2007013595A (es) * 2005-05-04 2008-01-24 Renovis Inc Compuestos heterociclicos fusionados y composiciones y usos de estos.
WO2007009911A1 (en) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
ATE482958T1 (de) * 2005-08-09 2010-10-15 Irm Llc Verbindungen und zusammensetzungen als proteinkinaseinhibitoren
WO2007022946A1 (de) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
CN101454319B (zh) * 2006-05-26 2012-06-27 富山化学工业株式会社 新杂环化合物或其盐及其中间体
WO2008150260A1 (en) * 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
US8022085B2 (en) 2007-05-07 2011-09-20 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
CA2690327A1 (en) 2007-06-15 2008-12-18 Thomas P. Cleary A novel process for the preparation of 3-amino-pentan-1,5-diol
US8367671B2 (en) 2008-03-21 2013-02-05 Amgen Inc. Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
JP2012505927A (ja) * 2008-10-22 2012-03-08 エフ．ホフマン−ラ ロシュ アーゲー Ｊｎｋのピリミジニルピリドン阻害剤
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
JP2013507395A (ja) 2009-10-09 2013-03-04 アフラクシス・インコーポレイテッド Ｃｎｓ障害治療用の８−エチル−６−（アリール）ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オン
US8889696B2 (en) * 2009-12-18 2014-11-18 Temple University—Of the Commonwealth System of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
KR20170032244A (ko) 2014-07-26 2017-03-22 선샤인 레이크 파르마 컴퍼니 리미티드 Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
ES2866883T3 (es) * 2016-06-08 2021-10-20 Support Venture Gmbh Combinaciones farmacéuticas para el tratamiento del cáncer
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
CA3033887A1 (en) * 2016-08-17 2018-02-22 Support-Venture Gmbh Method of preventing or treating hearing loss
US11117858B2 (en) 2017-01-11 2021-09-14 The General Hospital Corporation Voltage gated sodium channel imaging agents
CN110636840A (zh) 2017-04-04 2019-12-31 斯特里金股份公司 预防或治疗眼科疾病的方法
CN111032655B (zh) * 2017-08-31 2022-09-02 达纳-法伯癌症研究所股份有限公司 Egfr和/或her2抑制剂和使用方法
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2020006210A1 (en) * 2018-06-27 2020-01-02 Tufts Medical Center, Inc. Pyridopyrimidine compounds and methods of their use
SG11202012775SA (en) 2018-07-13 2021-02-25 Kinarus Ag Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2022034031A1 (en) 2020-08-11 2022-02-17 Kinarus Ag Methods of preventing or treating covid-19 and related viral diseases or disorders
CN120247910A (zh) * 2025-04-01 2025-07-04 赣南师范大学 一种杂环类化合物及其制备方法、应用和防治肿瘤的药物组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215216A (en) 1979-04-18 1980-07-29 American Home Products Corporation 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives
US5037826A (en) 1986-10-15 1991-08-06 Schering Corporation 1-substituted naphthyridine and pyridopyrazine derivatives
GB8702758D0 (en) * 1987-02-06 1987-03-11 Wellcome Found Treatment of disease
AU598093B2 (en) 1987-02-07 1990-06-14 Wellcome Foundation Limited, The Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
ATE194985T1 (de) * 1990-11-06 2000-08-15 Yamanouchi Pharma Co Ltd Kondensiertes pyrazinderivat
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
TW299333B (https=) * 1992-12-29 1997-03-01 Takeda Pharm Industry Co Ltd
HUT76853A (en) * 1994-11-14 1997-12-29 Warner Lambert Co 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
AU7108398A (en) 1997-04-16 1998-11-11 Abbott Laboratories 5,7-disubstituted 4-aminopyrido{2,3-d}pyrimidine compounds and their use as adenosine kinase inhibitors
TR199902550T2 (xx) 1997-04-16 2000-04-21 Abbott Laboratories 5, 6, 7-Tris�bstit�e -4-aminopirido $2,3-D] pirimidin bile�ikleri.
TW458977B (en) * 1997-04-16 2001-10-11 Abbott Lab 6,7-disubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
AU763839B2 (en) 1998-05-26 2003-07-31 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
BR9911365A (pt) 1998-06-19 2001-03-13 Pfizer Prod Inc Compostos pirrolo[2,3-d]pirimidina
EP1078923B1 (en) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
PL358271A1 (pl) * 2000-03-06 2004-08-09 Warner-Lambert Company 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny
US6518276B2 (en) * 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
DE60206363T2 (de) 2001-02-12 2006-07-06 F. Hoffmann-La Roche Ag 6-substituierte pyridopyrimidine
ES2251677T3 (es) * 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003237009B2 (en) * 2002-01-22 2008-10-02 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3d]pyrimidin-7-ones

Also Published As

Publication number Publication date
ES2249574T3 (es) 2006-04-01
JO2410B1 (en) 2007-06-17
DE60206363T2 (de) 2006-07-06
NO326133B1 (no) 2008-10-06
HK1066170A1 (en) 2005-03-18
ZA200305938B (en) 2005-01-26
YU63703A (sh) 2006-05-25
SK11322003A3 (en) 2004-10-05
MXPA03007166A (es) 2003-11-18
MY131518A (en) 2007-08-30
PL366918A1 (en) 2005-02-07
CN1503672A (zh) 2004-06-09
US20070135458A1 (en) 2007-06-14
NZ526961A (en) 2005-03-24
KR20040018254A (ko) 2004-03-02
IL156872A0 (en) 2004-02-08
HRP20030624B1 (en) 2007-03-31
HUP0303458A2 (hu) 2004-01-28
HU229604B1 (en) 2014-02-28
BRPI0207172B8 (pt) 2021-05-25
JP4064818B2 (ja) 2008-03-19
US20040116698A1 (en) 2004-06-17
DE60206363D1 (de) 2006-02-09
CN100376571C (zh) 2008-03-26
CA2434834A1 (en) 2002-08-22
PA8539201A1 (es) 2004-08-31
BR0207172A (pt) 2004-03-30
EP1361880B1 (en) 2005-09-28
JP2004525896A (ja) 2004-08-26
RU2269527C2 (ru) 2006-02-10
ATE305303T1 (de) 2005-10-15
HRP20030624A2 (en) 2005-06-30
RU2003125887A (ru) 2005-03-20
US7169794B2 (en) 2007-01-30
US7449581B2 (en) 2008-11-11
WO2002064594A2 (en) 2002-08-22
MA26993A1 (fr) 2004-12-20
PE20020976A1 (es) 2002-10-29
KR100639772B1 (ko) 2006-10-30
CA2434834C (en) 2010-09-14
AR035854A1 (es) 2004-07-21
HUP0303458A3 (en) 2012-12-28
CZ20032416A3 (cs) 2004-07-14
NO20033540D0 (no) 2003-08-11
NO20033540L (no) 2003-08-11
WO2002064594A3 (en) 2003-01-09
EP1361880A2 (en) 2003-11-19
US6696566B2 (en) 2004-02-24
IL156872A (en) 2009-07-20
DK1361880T3 (da) 2006-01-23
US20030171584A1 (en) 2003-09-11
BRPI0207172B1 (pt) 2019-04-09

Similar Documents

Publication Publication Date Title
AU2002256615B2 (en) 6-substituted pyrido-pyrimidines
EP1539755B1 (en) 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
AU2002256615A1 (en) 6-substituted pyrido-pyrimidines
AU2001293784B2 (en) 7-OXO pyridopyrimidines as inhibitors of a cellular proliferation
US7750016B2 (en) Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
BG108085A (bg) 6-заместени пиридо-пиримидини
HK1066170B (en) 6-substituted pyrido-pyrimidines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired